NJH secures $12.7m grant to develop AEOL 10150
The contract also supports the research on plasminogen activator (TPA) and Silabilin as MCM’s against sulfur mustard gas exposure. AEOL can also be used to treat pulmonary injuries
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.